TSBX - Turnstone Biologics Corp.


0.355
0.005   1.408%

Share volume: 283,774
Last Updated: 08-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%

$0.35
0.01
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
35%
Profitability 43%
Dept financing 7%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-8.32%
2 Year
-89.34%
Key data
Stock price
$0.36
P/E Ratio 
0.00
DAY RANGE
$0.35 - $0.36
EPS 
-$1.43
52 WEEK RANGE
$0.29 - $0.43
52 WEEK CHANGE
$0.25
MARKET CAP 
9.487 M
YIELD 
N/A
SHARES OUTSTANDING 
23.140 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
-0.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Sammy Farah
Region: US
Website: turnstonebio.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. Turnstone Biologics Inc. was incorporated as a Canadian corporation on March 27, 2014. On December 13, 2018, we incorporated Turnstone Biologics Corp., a corporation under the laws of the State of Delaware. On December 14, 2018, we completed a reorganization from Canada to the United States, which we refer to as the Reorganization. In connection with the Reorganization, all of the shareholders of Turnstone Canada exchanged their shares in Turnstone Canada for shares of our new incorporated Delaware entity, as a result of which Turnstone Canada became our wholly owned subsidiary. Our principal executive offices are located at 9310 Athena Circle, Suite 300, La Jolla, California.

Recent news